Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BIO-11006
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BIO-11006 demonstrated safety and a 43 percent reduction in all-cause mortality at 28 days in ARDS.
Product Name : BIO-11006
Product Type : Peptide
Upfront Cash : Inapplicable
April 23, 2020
Lead Product(s) : BIO-11006
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACQT1127
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The patent covers compounds that are intended to help patients with gout, NASH (nonalcoholic steatohepatitis), and other illnesses.
Product Name : ACQT1127
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : ACQT1127
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data to be presented showed that inhaled BIO-11006 decreases metastasis and tumor progression, and increases the overall response rate and survival in patients with advanced NSCLC.
Product Name : BIO-11006
Product Type : Peptide
Upfront Cash : Inapplicable
January 06, 2020